Other therapy.

Decentralization of Next-Generation RNA Sequencing-Based MammaPrintยฎ and BluePrintยฎ Kit at University Hospitals Leuven and Curie Institute Paris.

PUBLICATION: Transl Oncol. 2019 Sep 9;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. AUTHORS: Slembrouck Read More

2024-03-25T08:36:04-04:00September 9th, 2019|Evidence, MammaPrint, Other, Validation|

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More

2024-03-25T08:36:57-04:00September 1st, 2019|BluePrint, Evidence, MammaPrint, Other, Validation|

Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial

PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More

2024-03-25T08:46:25-04:00August 2nd, 2019|Adjuvant, Evidence, MammaPrint, MINDACT, Other, Validation|

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More

2024-03-25T08:56:28-04:00March 27th, 2019|BluePrint, Evidence, Other, Validation|

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Read More

2024-03-27T10:20:24-04:00April 18th, 2018|BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other|

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep Read More

2024-03-25T09:00:19-04:00September 22nd, 2017|BluePrint, Evidence, MammaPrint, Other, Validation|
Go to Top